Corvus Pharmaceuticals, Inc. 10-Q

Item 1. Financial Statements (unaudited) 3 ​ ​ Condensed Consolidated Balance Sheets 3 ​ ​ Condensed Consolidated Statements of Operations and Comprehensive Loss 4 ​ ​ Condensed Consolidated Statements of Change in Stockholders’ Equity 5 ​ ​ Condensed Consolidated Statements of Cash Flows 6 ​ ​ Notes to Condensed Consolidated Financial Statements 7 Item 2. ​ Management’s Discussion and Analysis of Financial Condition and Results of Operations 20 Item 3. ​ Quantitative and Qualitative Disclosures About Market Risk 33 Item 4 ​ Controls and Procedures 33 ​ ​ ​ ​ PART II — OTHER INFORMATION ​ ​ ​ ​ Item 1. ​ Legal Proceedings 35 Item 1A. ​ Risk Factors 35 Item 2. ​ Unregistered Sales of Equity Securities and Use of Proceeds 82 Item 3. ​ Defaults Upon Senior Securities 82 Item 4. ​ Mine Safety Disclosures 82 Item 5. ​ Other Information 82 Item 6. ​ Exhibits 83 ​ ​ ​ ​ SIGNATURES 84 ​ ​ 2 Table of Contents PART I - FINANCIAL INFORMATION ​ Item 1. Unaudited Condensed Financial Statements ​ CORVUS PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share data) (unaudited) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ December 31, ​ 2020 2019 Assets ​ ​ Current assets: ​ ​ Cash and cash equivalents ​ $ 22,976 ​ $ 5,154 Marketable securities ​ 28,385 ​ 72,828 Prepaid and other current assets ​ 1,148 ​ 1,362 Total current assets ​ 52,509 ​ 79,344 Property and equipment, net ​ 1,048 ​ 1,462 Operating lease right-of-use asset ​ ​ 1,825 ​ ​ 2,327 Other assets ​ ​ 480 ​ ​ 513 Total assets ​ $ 55,862 ​ $ 83,646 ​ ​ ​ ​ ​ ​ ​ Liabilities and Stockholders’ Equity ​ ​ ​ Current liabilities: ​ ​ Accounts payable ​ $ 2,571 ​ $ 2,448 Operating lease liability ​ ​ 1,026 ​ ​ 878 Accrued and other liabilities ​ 8,404 ​ 6,899 Total current liabilities ​ 12,001 ​ 10,225 Operating lease liability ​ ​ 1,511 ​ ​ 2,310 Total liabilities ​ 13,512 ​ 12,535 Commitments and contingencies (Note 12) ​ ​ Stockholders’ equity: ​ ​ Preferred stock: $ 0.0001 par value; 10,000,000 shares authorized at September 30, 2020 and December 31, 2019; 0 shares issued and outstanding at September 30, 2020 and December 31, 2019 ​ ​ — ​ ​ — Common stock: $ 0.0001 par value; 290,000,000 shares authorized at September 30, 2020 and December 31, 2019; 28,059,900 and 27,953,233 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively ​ 3 ​ 3 Additional paid-in capital ​ 292,822 ​ 288,224 Accumulated other comprehensive income ​ 12 ​ 29 Accumulated deficit ​ ( 250,487 ) ​ ( 217,145 ) Total stockholders’ equity ​ 42,350 ​ 71,111 Total liabilities and stockholders’ equity ​ $ 55,862 ​ $ 83,646 ​ The accompanying notes are an integral part of these condensed consolidated financial statements. ​ 3 Table of Contents CORVUS PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (in thousands, except share and per share data) (unaudited) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Nine Months Ended ​ ​ ​ September 30, ​ September 30, ​ ​ 2020 2019 2020 2019 Operating expenses: ​ ​ ​ ​ ​ ​ ​ Research and development ​ $ 6,619 ​ $ 8,996 ​ $ 24,639 ​ $ 29,055 ​ General and administrative ​ 3,226 ​ 2,517 ​ 9,242 ​ 8,359 ​ Total operating expenses ​ 9,845 ​ 11,513 ​ 33,881 ​ 37,414 ​ Loss from operations ​ ( 9,845 ) ​ ( 11,513 ) ​ ( 33,881 ) ​ ( 37,414 ) ​ Interest income and other expense, net ​ 49 ​ 509 ​ 539 ​ 1,789 ​ Net loss ​ $ ( 9,796 ) ​ $ ( 11,004 ) ​ $ ( 33,342 ) ​ $ ( 35,625 ) ​ Net loss per share, basic and diluted ​ $ ( 0.33 ) ​ $ ( 0.37 ) ​ $ ( 1.13 ) ​ $ ( 1.21 ) ​ Shares used to compute net loss per share, basic and diluted ​ 29,500,318 ​ 29,389,003 ​ 29,419,431 ​ 29,331,290 ​ Other comprehensive loss: ​ ​ ​ ​ ​ ​ ​ Unrealized gain (loss) on marketable securities ​ ( 41 ) ​ ( 5 ) ​ ( 17 ) ​ 68 ​ Comprehensive loss ​ $ ( 9,837 ) ​ $ ( 11,009 ) ​ $ ( 33,359 ) ​ $ ( 35,557 ) ​ ​ The accompanying notes are an integral part of these condensed consolidated financial statements. ​ ​ ​ 4 Table of Contents CORVUS PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (in thousands, except share data) (unaudited) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine Months Ended September 30, 2020 ​ ​ ​ ​ ​ ​ ​ Accumulated ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Additional ​ Other ​ ​ ​ ​ Total ​ ​ Common Stock ​ Paid-in ​ Comprehensive ​ Accumulated ​ Stockholders’ ​ Shares Amount Capital Income Deficit Equity Balance at December 31, 2019 ​ 27,953,233 ​ $ 3 ​ $ 288,224 ​ $ 29 ​ $ ( 217,145 ) ​ $ 71,111 Stock-based compensation expense ​ — ​ ​ — ​ ​ 1,845 ​ ​ — ​ ​ — ​ ​ 1,845 Unrealized gain on marketable securities ​ — ​ ​ — ​ ​ — ​ ​ 14 ​ ​ — ​ ​ 14 Net loss ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ ( 12,935 ) ​ ​ ( 12,935 ) Balance at March 31, 2020 ​ 27,953,233 ​ $ 3 ​ $ 290,069 ​ $ 43 ​ $ ( 230,080 ) ​ $ 60,035 Common stock issued on exercise of stock options ​ 81,500 ​ ​ — ​ ​ 23 ​ ​ — ​ ​ — ​ ​ 23 Stock-based compensation expense ​ — ​ ​ — ​ ​ 1,383 ​ ​ — ​ ​ — ​ ​ 1,383 Unrealized gain on marketable securities ​ — ​ ​ — ​ ​ — ​ ​ 10 ​ ​ — ​ ​ 10 Net loss ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ ( 10,611 ) ​ ​ ( 10,611 ) Balance at June 30, 2020 ​ 28,034,733 ​ $ 3 ​ $ 291,475 ​ $ 53 ​ $ ( 240,691 ) ​ $ 50,840 Common stock issued on exercise of stock options ​ 25,167 ​ ​ — ​ ​ 64 ​ ​ — ​ ​ — ​ ​ 64 Vesting of restricted stock for early exercise of stock options ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Stock-based compensation expense ​ — ​ ​ — ​ ​ 1,283 ​ ​ — ​ ​ — ​ ​ 1,283 Unrealized loss on marketable securities ​ — ​ ​ — ​ ​ — ​ ​ ( 41 ) ​ ​ — ​ ​ ( 41 ) Net loss ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ ( 9,796 ) ​ ​ ( 9,796 ) Balance at September 30, 2020 ​ 28,059,900 ​ $ 3 ​ $ 292,822 ​ $ 12 ​ $ ( 250,487 ) ​ $ 42,350 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine Months Ended September 30, 2019 ​ ​ ​ ​ ​ ​ ​ Accumulated ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Additional ​ Other ​ ​ ​ ​ Total ​ ​ Common Stock ​ Paid-in ​ Comprehensive ​ Accumulated ​ Stockholders’ ​ Shares Amount Capital Income Deficit Equity Balance at December 31, 2018 ​ 29,323,930 ​ $ 3 ​ $ 280,840 ​ $ ( 34 ) ​ $ ( 170,473 ) ​ $ 110,336 Common stock issued on exercise of stock options ​ 2,970 ​ ​ — ​ ​ 1 ​ ​ — ​ ​ — ​ ​ 1 Vesting of restricted stock for early exercise of stock options ​ — ​ ​ — ​ ​ 5 ​ ​ — ​ ​ — ​ ​ 5 Stock-based compensation expense ​ — ​ ​ — ​ ​ 1,953 ​ ​ — ​ ​ — ​ ​ 1,953 Unrealized gain on marketable securities ​ — ​ ​ — ​ ​ — ​ ​ 45 ​ ​ — ​ ​ 45 Net loss ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ ( 11,643 ) ​ ​ ( 11,643 ) Balance at March 31, 2019 ​ 29,326,900 ​ $ 3 ​ $ 282,799 ​ $ 11 ​ $ ( 182,116 ) ​ $ 100,697 Common stock issued on exercise of stock options ​ 21,500 ​ ​ — ​ ​ 5 ​ ​ — ​ ​ — ​ ​ 5 Vesting of restricted stock for early exercise of stock options ​ — ​ ​ — ​ ​ 4 ​ ​ — ​ ​ — ​ ​ 4 Stock-based compensation expense ​ — ​ ​ — ​ ​ 1,898 ​ ​ — ​ ​ — ​ ​ 1,898 Unrealized gain on marketable securities ​ — ​ ​ — ​ ​ — ​ ​ 28 ​ ​ — ​ ​ 28 Net loss ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ ( 12,978 ) ​ ​ ( 12,978 ) Balance at June 30, 2019 ​ 29,348,400 ​ $ 3 ​ $ 284,706 ​ $ 39 ​ $ ( 195,094 ) ​ $ 89,654 Common stock issued on exercise of stock options ​ 57,000 ​ ​ — ​ ​ 16 ​ ​ — ​ ​ — ​ ​ 16 Vesting of restricted stock for early exercise of stock options ​ — ​ ​ — ​ ​ 3 ​ ​ — ​ ​ — ​ ​ 3 Stock-based compensation expense ​ — ​ ​ — ​ ​ 1,749 ​ ​ — ​ ​ — ​ ​ 1,749 Unrealized loss on marketable securities ​ — ​ ​ — ​ ​ — ​ ​ ( 5 ) ​ ​ — ​ ​ ( 5 ) Net loss ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ ( 11,004 ) ​ ​ ( 11,004 ) Balance at September 30, 2019 ​ 29,405,400 ​ $ 3 ​ $ 286,474 ​ $ 34 ​ $ ( 206,098 ) ​ $ 80,413 ​ The accompanying notes are an integral part of these condensed consolidated financial statements. ​ 5 Table of Contents CORVUS PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands) (unaudited) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine Months Ended ​ ​ ​ September 30, ​ ​ 2020 2019 Cash flows from operating activities ​ ​ ​ ​ Net loss ​ $ ( 33,342 ) ​ $ ( 35,625 ) ​ Adjustments to reconcile net loss to net cash used in operating activities: ​ ​ ​ Depreciation and amortization ​ 490 ​ 558 ​ Accretion related to marketable securities ​ 44 ​ ( 565 ) ​ Stock-based compensation ​ 4,511 ​ 5,600 ​ Changes in operating assets and liabilities: ​ ​ ​ Prepaid and other current assets ​ 214 ​ ( 419 ) ​ Operating lease right-of-use asset ​ ​ 502 ​ ​ 443 ​ Other assets ​ ​ 33 ​ ​ ( 50 ) ​ Accounts payable ​ 123 ​ ( 88 ) ​ Accrued and other liabilities ​ 1,505 ​ 1,903 ​ Operating lease liability ​ ​ ( 651 ) ​ ​ ( 568 ) ​ Net cash used in operating activities ​ ( 26,571 ) ​ ( 28,811 ) ​ Cash flows from investing activities ​ ​ ​ Purchases of marketable securities ​ ( 35,464 ) ​ ( 114,873 ) ​ Sales of marketable securities ​ ​ 1,009 ​ ​ — ​ Maturities of marketable securities ​ 78,837 ​ 113,553 ​ Purchases of property and equipment ​ ( 76 ) ​ ( 20 ) ​ Net cash provided by investing activities ​ 44,306 ​ ( 1,340 ) ​ Cash flows from financing activities ​ ​ ​ Proceeds from exercise of common stock options ​ 87 ​ 22 ​ Net cash provided by financing activities ​ 87 ​ 22 ​ Net increase (decrease) in cash and cash equivalents ​ 17,822 ​ ( 30,129 ) ​ Cash and cash equivalents at beginning of the period ​ 5,154 ​ 39,196 ​ Cash and cash equivalents at end of the period ​ $ 22,976 ​ $ 9,067 ​ ​ The accompanying notes are an integral part of these condensed consolidated financial statements. ​ ​ ​ ​ ​ 6 Table of Contents CORVUS PHARMACEUTICALS, INC. ​ NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited) ​ 1. Organization ​ Corvus Pharmaceuticals, Inc. (“Corvus” or the “Company”) was incorporated in Delaware on January 27, 2014 and commenced operations in November 2014. Corvus is a clinical-stage biopharmaceutical company. The Company’s operations are located in Burlingame, California. The Company has three insignificant subsidiaries. ​ Initial Public Offering ​ On March 22, 2016, the Company’s registration statement on Form S-1 (File No. 333-208850) relating to its initial public offering (“IPO”) of its common stock was declared effective by the Securities and Exchange Commission (“SEC”) and the shares of its common stock began trading on the Nasdaq Global Market on March 23, 2016. The public offering price of the shares sold in the IPO was $ 15.00 per share. The IPO closed on March 29, 2016, pursuant to which the Company sold 4,700,000 shares of its common stock. On April 26, 2016, the Company sold an additional 502,618 shares of its common stock to the underwriters upon partial exercise of their over-allotment option, at the initial offering price of $ 15.00 per share. The Company received aggregate net proceeds of approximately $ 70.6 million, after underwriting discounts, commissions and offering expenses. Immediately prior to the consummation of the IPO, all outstanding shares of convertible preferred stock were converted into common stock. ​ Follow-on Public Offering ​ In March 2018, the Company completed a follow-on public offering in which the Company sold 8,117,647 shares of common stock at a price of $ 8.50 per share, which included 1,058,823 shares issued pursuant to the underwriters’ exercise of their option to purchase additional shares of common stock. The aggregate net proceeds received by the Company from the offering were approximately $ 64.9 million, net of underwriting discounts and commissions and offering expenses payable by the Company. ​ Liquidity ​ The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, contract manufacturer and contract research organizations, compliance with government regulations and the need to obtain additional financing to fund operations. Since commencing operations in 2014, the majority of the Company’s efforts have been focused on the research and development of ciforadenant, CPI-006 and CPI-818. The Company believes that it will continue to expend substantial resources for the foreseeable future as it continues clinical development of, seek regulatory approval for and, if approved, prepare for the commercialization of ciforadenant, CPI-006, and CPI-818, as well as product candidates under the Company’s other development programs. These expenditures will include costs associated with research and development, conducting preclinical studies and clinical trials, obtaining regulatory approvals, manufacturing and supply, sales and marketing and general operations. In addition, other unanticipated costs may arise. Because the outcome of any clinical trial and/or regulatory approval process is highly uncertain, the Company may not be able to accurately estimate the actual amounts necessary to successfully complete the development, regulatory approval process and commercialization of ciforadenant, CPI-006, CPI-818 or any other product candidates. The Company does not expect its existing capital resources to be sufficient to enable it to fund the completion of all of its ongoing or planned clinical trials and remaining development program of ciforadenant, CPI-006 or CPI-818 through commercialization. In addition, its operating plan may change as a result of many factors, including those described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 filed on March 9, 2020. The Company has incurred significant losses and negative cash flows from operations in all periods since inception and had an accumulated deficit of $ 250.5 million as of September 30, 2020. The Company has historically financed its operations primarily through the sale of redeemable convertible preferred stock and common stock. While 7 Table of Contents the Company has been able to raise multiple rounds of financing, there can be no assurance that in the event the Company requires additional financing, such financing will be available on terms which are favorable or at all. Failure to generate sufficient cash flows from operations, raise additional capital or reduce certain discretionary spending would have a material adverse effect on the Company’s ability to achieve its intended business objectives. As of September 30, 2020, the Company had cash, cash equivalents and short-term marketable securities of $ 51.4 million. Management believes that the Company’s current cash, cash equivalents and short-term marketable securities will be sufficient to fund its planned operations for at least 12 months from the date of the issuance of these financial statements. The current COVID-19 (coronavirus) pandemic, which is impacting worldwide economic activity, poses risks that the Company or its employees, contractors, suppliers, and other partners may be prevented from conducting business activities for an indefinite period of time, including due to shutdowns that may be requested or mandated by governmental authorities. The extent to which COVID-19 impacts the Company’s business, including its clinical trials and financial condition, will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the pandemic, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease. As COVID-19 continues to spread around the globe, we will likely experience disruptions, including delays or difficulties in enrolling patients in our clinical trials, delays or difficulties in clinical site initiation, interruption of key clinical trial activities, delays in clinical sites receiving the supplies and materials needed to conduct our clinical trials and delays in necessary interactions with local regulatory authorities. COVID-19 may also impact the Company’s ability to raise additional capital on a timely basis or at all, which could negatively impact short-term and long-term liquidity. Exchange Warrants ​ On November 8, 2019, the Company entered into an exchange agreement (the “Exchange Agreement”) with an Investor and its affiliates (the “Exchanging Stockholders”), pursuant to which the Company exchanged an aggregate of 1,458,000 shares of the Company’s common stock, par value $ 0.0001 per share, owned by the Exchanging Stockholders for pre-funded warrants (the “Exchange Warrants”) to purchase an aggregate of 1,458,000 shares of common stock (subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction, as described in the Exchange Warrants), with an exercise price of $ 0.0001 per share. The Exchange Warrants will expire ten years from the date of issuance. The Exchange Warrants are exercisable at any time prior to expiration except that the Exchange Warrants cannot be exercised by the Exchanging Stockholders if, after giving effect thereto, the Exchanging Stockholders would beneficially own more than 9.99 % of the Company’s common stock, subject to certain exceptions. In accordance with Accounting Standards Codification Topic 505, Equity, and Accounting Research Bulletin 43, the Company recorded the retirement of the common stock exchanged as a reduction of common shares outstanding and elected to record the excess over par value as a debit to additional paid-in-capital at the fair value of the Exchange Warrants on the issuance date. The Exchange Warrants are classified as equity in accordance with Accounting Standards Codification Topic 480, Distinguishing Liabilities from Equity, and Accounting Standards Codification Topic 815, Derivatives and Hedging, and the fair value of the Exchange Warrants was recorded as a credit to additional paid-in capital and is not subject to remeasurement. The Company determined that the fair value of the Exchange Warrants is substantially similar to the fair value of the retired shares on the issuance date due to the negligible exercise price for the Exchange Warrants. As of September 30, 2020, none of the Exchange Warrants have been exercised. ​ 2. Summary of Significant Accounting Policies ​ Basis of Presentation ​ The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The Company’s functional and reporting currency is the U.S. dollar. The accompanying condensed consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and discharge of liabilities in the normal 8 Table of Contents course of business. Since its inception, the Company has incurred significant losses and negative cash flows from operations. As of September 30, 2020, the Company had an accumulated deficit of $ 250.5 million and cash, cash equivalents and marketable securities of $ 51.4 million. The Company has financed its operations primarily with the proceeds from the sale of stock. The Company will need to raise additional capital to meet its business objectives. The Company believes that its current cash, cash equivalents and marketable securities will be sufficient to fund its planned expenditures and meet its obligations through at least the next twelve months from the issuance of these financial statements. ​ Unaudited Interim Financial Information ​ The accompanying interim condensed consolidated financial statements and related disclosures are unaudited, have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the results of operations for the periods presented. ​ The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. The condensed consolidated results of operations for the nine months ended September 30, 2020 are not necessarily indicative of the results to be expected for the full year or for any other future year or interim period. The accompanying condensed consolidated financial statements should be read in conjunction with the audited financial statements and the related notes for the year ended December 31, 2019 included in the Company’s Annual Report on Form 10-K filed with the SEC on March 9, 2020. ​ Use of Estimates ​ The preparation of the Company’s condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from such estimates. ​ Concentrations of Credit Risk and Other Risks and Uncertainties ​ Substantially all of the Company’s cash and cash equivalents are deposited in accounts with two financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. The Company maintains its cash with an accredited financial institution and accordingly, such funds are subject to minimal credit risk. The Company’s marketable securities consist of investments in U.S. Treasury securities, U.S. government agency securities and corporate debt obligations, which can be subject to certain credit risks. However, the Company mitigates the risks by investing in high-grade instruments, limiting its exposure to any one issuer, and monitoring the ongoing creditworthiness of the financial institutions and issuers. The Company has not experienced any losses on its deposits of cash, cash equivalents or marketable securities. ​ The Company is subject to a number of risks similar to other early stage biopharmaceutical companies, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, its reliance on third parties to conduct its clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company’s product candidates, its right to develop and commercialize its product candidates pursuant to the terms and conditions of the licenses granted to the Company, and protection of proprietary technology. If the Company does not successfully commercialize or partner any of its product candidates, it will be unable to generate product revenue or achieve profitability. ​ Segments ​ Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment, that of the development of and commercialization of precisely targeted oncology therapies. 9 Table of Contents ​ Significant Accounting Policies ​ The Company’s significant accounting policies are described in Note 2 to its consolidated financial statements for the year ended December 31, 2019, included in its Annual Report on Form 10-K. There have been no material changes to the Company’s significant accounting policies during the nine months ended September 30, 2020. ​ Recent Accounting Pronouncements ​ In February 2016, the Financial Accounting Standards Board issued ASU No. 2016-02, Leases (Topic 842), which requires lessees to recognize leases on-balance sheet and disclose key information about leasing arrangements. Topic 842 was subsequently amended by ASU No. 2018-01, Land Easement Practical Expedient for Transition to Topic 842; ASU No. 2018-10, Codification Improvements to Topic 842, Leases; and ASU No. 2018-11, Targeted Improvements. The new standard establishes a right-of-use (ROU) model that requires a lessee to recognize an ROU asset and lease liability on the balance sheet. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the statement of operations. The Company adopted the new standard on January 1, 2019 and has elected the ‘package of practical expedients’, which permit it not to reassess under the new standard its prior conclusions about lease identification, lease classification and initial direct costs. The Company did not elect the use-of-hindsight or the practical expedient pertaining to land easements; the latter is not applicable to the Company. Upon adoption of ASU 2016-02, the Company recognized an operating lease, right-of-use asset of $ 2.8 million and a corresponding liability of $ 3.8 million and eliminated $ 1.0 million of deferred rent in the Company’s condensed balance sheet. The adoption of ASU 2016-02 did not have any impact on the Company’s condensed statements of operations and comprehensive loss. See also Note 11. ​ ​ 3. Net Loss per Share ​ The following table shows the calculation of net loss per share (in thousands, except share and per share data): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Nine Months Ended ​ ​ ​ September 30, ​ September 30, ​ ​ 2020 2019 2020 2019 Numerator: ​ ​ ​ ​ ​ ​ ​ Net loss - basic and diluted ​ $ ( 9,796 ) ​ $ ( 11,004 ) ​ $ ( 33,342 ) ​ $ ( 35,625 ) ​ Denominator: ​ ​ ​ ​ ​ ​ ​ Weighted average common shares outstanding ​ 29,500,318 ​ 29,394,639 ​ 29,419,431 ​ 29,350,507 ​ Less: weighted average common shares subject to repurchase ​ — ​ ( 5,636 ) ​ — ​ ( 19,217 ) ​ Weighted average common shares outstanding used to compute basic and diluted net loss per share ​ 29,500,318 ​ 29,389,003 ​ 29,419,431 ​ 29,331,290 ​ Net loss per share, basic and diluted ​ $ ( 0.33 ) ​ $ ( 0.37 ) ​ $ ( 1.13 ) ​ $ ( 1.21 ) ​ ​ Weighted average common shares outstanding for the three and nine months ended September 30, 2020 include 1,458,000 shares of common stock issuable on the conversion of pre-funded warrants described in Note 1. ​ The amounts in the table below were excluded from the calculation of diluted net loss per share, due to their anti-dilutive effect: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Nine Months Ended ​ ​ ​ September 30, ​ September 30, ​ ​ 2020 2019 2020 2019 Outstanding options ​ 5,387,868 4,091,919 ​ 5,387,868 4,091,919 ​ Total shares of common stock equivalents ​ 5,387,868 4,091,919 ​ 5,387,868 4,091,919 ​ ​ ​ 10 Table of Contents 4. Fair Value Measurements ​ Financial assets and liabilities are measured and recorded at fair value. The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. The fair value hierarchy prioritizes valuation inputs based on the observable nature of those inputs. The fair value hierarchy applies only to the valuation inputs used in determining the reported fair value of the investments and is not a measure of the investment credit quality. The hierarchy defines three levels of valuation inputs: ​ ● Level 1—Quoted prices in active markets for identical assets or liabilities ​ ● Level 2—Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly ​ ● Level 3 —Unobservable inputs that reflect the Company’s own assumptions about the assumptions market participants would use in pricing the asset or liability ​ There have been no transfers of assets and liabilities between levels of hierarchy. ​ The Company’s Level 2 investments are valued using third-party pricing sources. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar investments, issuer credit spreads, benchmark investments, prepayment/default projections based on historical data and other observable inputs. ​ The following tables present information as of September 30, 2020 and December 31, 2019 about the Company’s assets that are measured at fair value on a recurring basis and indicate the level of the fair value hierarchy the Company utilized to determine such fair values (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2020 ​ ​ Fair Value Measured Using ​ Total ​ (Level 1) (Level 2) (Level 3) Balance Assets ​ ​ ​ ​ Cash equivalents ​ $ 22,314 ​ $ — ​ $ — ​ $ 22,314 Marketable securities ​ 2,035 ​ 26,350 ​ — ​ 28,385 ​ ​ $ 24,349 ​ $ 26,350 ​ $ — ​ $ 50,699 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2019 ​ ​ Fair Value Measured Using ​ Total ​ (Level 1) (Level 2) (Level 3) Balance Assets ​ ​ ​ ​ Cash equivalents ​ $ 4,252 ​ $ — ​ $ — ​ $ 4,252 Marketable securities ​ ​ 7,023 ​ 65,805 ​ — ​ 72,828 ​ ​ $ 11,275 ​ $ 65,805 ​ $ — ​ $ 77,080 ​ As of September 30, 2020, marketable securities had a maximum remaining maturity of eleven months . ​ 11 Table of Contents As of September 30, 2020 and December 31, 2019, the fair value of available for sale marketable securities by type of security were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2020 ​ ​ ​ Gross Gross ​ ​ ​ ​ Amortized ​ Unrealized ​ Unrealized ​ Fair ​ ​ Cost ​ Gains ​ Losses ​ Value U.S. Treasury securities ​ $ 2,034 ​ $ 1 ​ $ — ​ $ 2,035 U.S. Government agency securities ​ ​ 22,085 ​ ​ 9 ​ ​ ( 2 ) ​ ​ 22,092 Corporate debt obligations ​ ​ 4,254 ​ ​ 4 ​ ​ — ​ ​ 4,258 ​ ​ $ 28,373 ​ $ 14 ​ $ ( 2 ) ​ $ 28,385 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2019 ​ ​ ​ Gross Gross ​ ​ ​ ​ Amortized ​ Unrealized ​ Unrealized ​ Fair ​ ​ Cost ​ Gains ​ Losses ​ Value U.S. Treasury securities ​ $ 7,019 ​ $ 4 ​ $ — ​ $ 7,023 U.S. Government agency securities ​ ​ 17,701 ​ ​ 16 ​ ​ — ​ ​ 17,717 Corporate debt obligations ​ ​ 48,079 ​ ​ 17 ​ ​ ( 8 ) ​ ​ 48,088 ​ ​ $ 72,799 ​ $ 37 ​ $ ( 8 ) ​ $ 72,828 ​ ​ 5. License and Collaboration Agreements ​ Scripps Licensing Agreement ​ In December 2014, the Company entered into a license agreement with The Scripps Research Institute (“Scripps”), pursuant to which it was granted a non-exclusive, world-wide license for all fields of use under Scripps’ rights in certain know-how and technology related to a mouse hybridoma clone expressing an anti-human CD73 antibody, and to progeny, mutants or unmodified derivatives of such hybridoma and any antibodies expressed by such hybridoma, from which we developed CPI-006. Scripps also granted the Company the right to grant sublicenses in conjunction with other proprietary rights the Company holds, or to others collaborating with or performing services for the Company. Under this license agreement, Scripps has agreed not to grant any additional commercial licenses with respect to such materials, other than march-in rights granted to the U.S. government. ​ Upon execution of the agreement, the Company made a one-time cash payment to Scripps of $ 10,000 in 2015 and is also obligated to pay a minimum annual fee to Scripps of $ 25,000 . The one-time cash payment was recorded as research and development expense as technological feasibility of the asset had not been established and there was no alternative future use. A minimum annual fee payment is due on each anniversary of the effective date of the agreement for the term of the agreement. The Company is also required to make performance-based cash payments upon successful completion of clinical and sales milestones. The aggregate potential milestone payments are $ 2.6 million. The Company is also required to pay royalties on net sales of licensed products (including CPI-006) sold by it, its affiliates and its sublicensees at a rate in the low-single digits. In addition, should the Company sublicense the rights licensed under the agreement, it has agreed to pay a percentage of sublicense revenue received at specified rates that start at double digit percentages and decrease to single digit percentages based on the elapsed time from the effective date of the agreement and the time of entry into such sublicense. To date, no milestone payments have been made. ​ The Company’s license agreement with Scripps will terminate upon expiration of its obligation to pay royalties to Scripps under the license agreement. The Company’s license agreement with Scripps is terminable by the consent of the parties, at will by the Company upon providing 90 days written notice to Scripps, or by Scripps for certain material breaches, or if the Company undergoes a bankruptcy event. In addition, Scripps may terminate the license on a product-by-product basis, or the entire agreement, if the Company fails to meet specified diligence obligations related to the development and commercialization of licensed products. Scripps may also terminate the agreement after the third anniversary of the effective date of the agreement if it reasonably believes, based on reports the Company provides to Scripps, that the Company has not used commercially reasonable efforts as required under the agreement, subject to a specified notice and cure period. 12 Table of Contents ​ Vernalis Licensing Agreement ​ In February 2015, the Company entered into a license agreement with Vernalis (R&D) Limited (“Vernalis”), which was subsequently amended as of November 5, 2015, and, pursuant to which the Company was granted an exclusive, worldwide license under certain patent rights and know-how, including a limited right to grant sublicenses, for all fields of use to develop, manufacture and commercialize products containing certain adenosine receptor antagonists, including ciforadenant (formerly CPI-444). Pursuant to this agreement, the Company made a one-time cash payment to Vernalis in the amount of $ 1.0 million, which was recorded as research and development expense as technological feasibility of the asset had not been established and there was no alternative future use. The Company is also required to make cash milestone payments to Vernalis upon the successful completion of clinical and regulatory milestones for licensed products depending on the indications for which such licensed products are developed and upon achievement of certain sales milestones. In February 2017, the Company made a milestone payment of $ 3.0 million to Vernalis following the expansion of a cohort of patients with renal cell cancer treated with single agent ciforadenant in the Company’s Phase 1/1b clinical trial. The aggregate potential milestone payments are approximately $ 220 million for all indications. ​ The Company has also agreed to pay Vernalis tiered incremental royalties based on the annual net sales of licensed products containing ciforadenant on a product-by-product and country-by-country basis, subject to certain offsets and reductions. The tiered royalty rates for products containing ciforadenant range from the mid-single digits up to the low-double digits on a country-by-country net sales basis. The royalties on other licensed products that do not include ciforadenant also increase with the amount of net sales on a product-by-product and country-by-country basis and range from the low-single digits up to the mid-single digits on a country-by-country net sales basis. The Company is also obligated to pay to Vernalis certain sales milestones as indicated above when worldwide net sales reach specified levels over an agreed upon time period. ​ The agreement will expire on a product-by-product and country-by-country basis upon the expiration of the Company’s payment obligations to Vernalis in respect of a particular product and country. Both parties have the right to terminate the agreement for an uncured material breach by the other party. The Company may also terminate the agreement at its convenience by providing 90 days written notice, provided that the Company has not received notice of its own default under the agreement at the time the Company exercises such termination right. Vernalis may also terminate the agreement if the Company challenges a licensed patent or undergoes a bankruptcy event. ​ Genentech Collaboration Agreements ​ In October 2015, the Company entered into a clinical trial collaboration agreement with Genentech to evaluate the safety, tolerability and preliminary efficacy of ciforadenant combined with Genentech’s investigational cancer immunotherapy, Tecentriq (atezolizumab), a fully humanized monoclonal antibody targeting protein programmed cell death ligand 1(“PD-L1”), in a variety of solid tumors in a Phase 1/1b clinical trial. Pursuant to this agreement, the Company will be responsible for the conduct and cost of the relevant studies, under the supervision of a joint development committee made up of representatives of the Company and representatives of Genentech. Genentech will supply Tecentriq. As part of the agreement, the Company granted Genentech certain rights of first negotiation to participate in future clinical trials that the Company may conduct evaluating the administration of ciforadenant in combination with an anti-PD-1 or anti-PD-L1 antibody. If the Company and Genentech do not reach agreement on the terms of any such participation by Genentech within a specified time period, the Company retains the right to collaborate with third parties in such activities. The Company also granted Genentech certain rights of first negotiation should it decide to license development and commercialization rights to ciforadenant. Should the Company and Genentech not reach agreement on the terms of such a license within a specified time period, it retains the right to enter into a license with another third party. ​ The Company and Genentech each have the right to terminate the agreement for material breach by the other party. In addition, the agreement may be terminated by either party due to safety considerations, if directed by a regulatory authority or if development of ciforadenant or Tecentriq is discontinued. Further, the agreement will expire after a set period of time following the provision by the Company of the final clinical study report to Genentech. 13 Table of Contents ​ In May 2017, the Company signed a second clinical trial collaboration agreement with Genentech. Under the second agreement, ciforadenant administered in combination with Tecentriq is being evaluated in a Phase 1b/2 randomized, controlled clinical study, known as Morpheus, as second-line therapy in patients with non-small cell lung cancer who are resistant and/or refractory to prior therapy with an anti-PD-(L)1 antibody. The patients in the Morpheus trial are currently in the follow-up phase of the trial. Genentech is responsible for the conduct of the study and the parties share the cost of the Morpheus trial, which began enrolling patients in the fourth quarter of 2017. The Company is responsible for supplying ciforadenant and retains global development and commercialization rights to ciforadenant. The Company and Genentech each have the right to terminate the agreement for material breach by the other party. In addition, the agreement may be terminated by either party due to safety considerations, if directed by a regulatory authority or if development of ciforadenant or Tecentriq is discontinued. ​ Monash License Agreement In April 2017, the Company entered into a license agreement with Monash University (Monash), pursuant to which the Company was granted an exclusive, sublicensable worldwide license under certain know-how, patent rights and other intellectual property rights controlled by Monash to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases. Upon execution of the agreement, the Company made a one-time cash payment to Monash of $ 275,000 and reimbursed Monash for certain patent prosecution costs incurred prior to execution of the agreement. The Company us also obligated to pay an annual license maintenance fee to Monash of $ 25,000 until a certain development milestone is met with respect to the licensed product, after which no further maintenance fee will be due. The Company is also required to make development and sales milestone payments to Monash with respect to the licensed products in the aggregate of up to $ 45.1 million. The Company is also required to pay to Monash tiered royalties on net sales of licensed products sold by it, its affiliates and its sublicensees at a rate ranging in the low-single digits. In addition, should the Company sublicense its rights under the agreement, the Company has agreed to pay a percentage of sublicense revenue received at specified rates that are currently at low double digit percentages and decrease to single digit percentages based on the achievement of development milestones. The term of the Company’s agreement with Monash continues until the expiration of its obligation to pay royalties to Monash thereunder. The license agreement is terminable at will by the Company upon providing 30 days written notice to Monash, or by either party for material breaches by the other party. In addition, Monash may terminate the entire agreement or convert the license to a non-exclusive license if the Company has materially breached our obligation to use commercially reasonable efforts to develop and commercialize a licensed product, subject to a specified notice and cure mechanism. ​ 14 Table of Contents 6. Balance Sheet Components (in thousands) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ December 31, ​ ​ 2020 2019 Prepaid and Other Current Assets ​ ​ ​ ​ ​ ​ ​ Interest receivable ​ $ 139 ​ $ 329 ​ Prepaid research and development manufacturing expenses ​ ​ 44 ​ ​ 240 ​ Prepaid facility expenses ​ ​ 160 ​ ​ 157 ​ Prepaid insurance ​ ​ 357 ​ ​ 150 ​ Other ​ 448 ​ 486 ​ ​ ​ $ 1,148 ​ $ 1,362 ​ Property and Equipment ​ ​ ​ ​ ​ ​ ​ Laboratory equipment ​ $ 2,472 ​ $ 2,396 ​ Computer equipment and purchased software ​ 142 ​ 142 ​ Leasehold improvements ​ 2,084 ​ 2,084 ​ ​ ​ 4,698 ​ 4,622 ​ Less: accumulated depreciation and amortization ​ ( 3,650 ) ​ ( 3,160 ) ​ ​ ​ $ 1,048 ​ $ 1,462 ​ Accrued and Other Liabilities ​ ​ ​ ​ ​ ​ ​ Accrued clinical trial related ​ $ 4,516 ​ $ 4,300 ​ Accrued manufacturing expense ​ 623 ​ 696 ​ Personnel related ​ 2,293 ​ 1,624 ​ Other ​ 972 ​ 279 ​ ​ ​ $ 8,404 ​ $ 6,899 ​ ​ ​ 7. Common Stock ​ As of September 30, 2020, the amended and restated certificate of incorporation authorizes the Company to issue 290 million shares of common stock and 10 million shares of preferred stock. ​ Each share of common stock is entitled to one vote. Common stockholders are entitled to dividends if and when declared by the board of directors. As of September 30, 2020, no dividends on common stock had been declared. ​ In March 2020, the Company entered into an open market sale agreement (the “Sales Agreement”) with Jefferies LLC (“Jefferies”) to sell shares of the Company’s common stock, from time to time, with aggregate gross sales proceeds of up to $ 50,000,000 , through an at-the-market equity offering program under which Jefferies will act as its sales agent. The issuance and sale of shares of common stock by the Company pursuant to the Sales Agreement are deemed an “at-the-market” offering under the Securities Act of 1933, as amended. Jefferies is entitled to compensation for its services equal to up to 3.0 % of the gross proceeds of any shares of common stock sold through Jefferies under the Sales Agreement. As of September 30, 2020, the Company had received no proceeds from the sale of shares of common stock pursuant to the Sales Agreement. ​ The Company has reserved shares of common stock for issuance as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ December 31, ​ ​ 2020 2019 Exchange warrants 1,458,000 ​ 1,458,000 Shares available for future option grants ​ 2,971,058 ​ 1,704,183 ​ Outstanding options 5,387,868 ​ 5,643,410 Shares reserved for employee stock purchase plan 400,000 ​ 400,000 Total 10,216,926 ​ 9,205,593 ​ ​ 15 Table of Contents 8. Stock Option Plans ​ In February 2014, the Company adopted the 2014 Equity Incentive Plan (the “2014 Plan”), which was subsequently amended in November 2014, July 2015 and September 2015, under which it granted incentive stock options (“ISOs”) or non-qualified stock options (“NSOs”). Terms of stock agreements, including vesting requirements, are determined by the board of directors or a committee authorized by the board of directors, subject to the provisions of the 2014 Plan. In general, awards granted by the Company vest over four years and have a maximum exercise term of 10 years . The 2014 Plan provides that grants must be at an exercise price of 100 % of fair market value of the Company’s common stock as determined by the board of directors on the date of the grant. ​ In connection with the consummation of the IPO in March 2016, the 2016 Equity Incentive Award Plan (the “2016 Plan”), became effective. Under the 2016 Plan, incentive stock options, non-statutory stock options, stock purchase rights and other stock-based awards may be granted. Terms of stock agreements, including vesting requirements, are determined by the board of directors or a committee authorized by the board of directors, subject to the provisions of the 2016 Plan. In general, awards granted by the Company vest over four years and have a maximum exercise term of 10 years . The 2016 Plan provides that grants must be at an exercise price of 100 % of fair market value of the Company’s common stock as determined by the board of directors on the date of the grant. In conjunction with adopting the 2016 Plan, the 2014 Plan was terminated and no further awards will be granted under the 2014 Plan. Options outstanding under the 2014 Plan as of the effective date of the 2016 Plan that are forfeited or lapse unexercised may be re-issued under the 2016 Plan, up to a maximum of 1,136,229 shares. ​ Activity under the Company’s stock option plans is set forth below: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Options Outstanding ​ ​ ​ Weighted ‑ ​ ​ Shares ​ ​ ​ Average ​ ​ Available ​ Number of ​ Exercise ​ for Grant Options Price Balance at December 31, 2019 1,704,183 5,643,410 ​ $ 8.05 Additional shares authorized 1,118,000 — ​ — Options granted ( 220,000 ) 220,000 ​ 2.68 Options exercised — ( 106,667 ) ​ 0.82 Options forfeited 368,875 ( 368,875 ) ​ 6.39 Balance at September 30, 2020 2,971,058 5,387,868 ​ $ 8.01 ​ ​ 9. Stock-Based Compensation ​ The Company’s results of operations include expenses relating to employee and non-employee stock-based awards as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Nine Months Ended ​ ​ ​ September 30, ​ September 30, ​ ​ 2020 2019 2020 2019 Research and development ​ $ 622 ​ $ 752 ​ $ 2,206 ​ $ 2,350 ​ General and administrative ​ 661 ​ 997 ​ 2,305 ​ 3,250 ​ Total ​ $ 1,283 ​ $ 1,749 ​ $ 4,511 ​ $ 5,600 ​ ​ ​ 10. Income Taxes ​ During the three and nine months ended September 30, 2020 and 2019, the Company recorded no income tax benefits for the net operating losses (NOLs) incurred due to the uncertainty of realizing a benefit from those items. The Company continues to maintain a full valuation allowance against its net deferred tax assets. ​ ​ 16 Table of Contents 11. Facility Lease ​ In January 2015, the Company signed an initial operating lease, effective February 1, 2015 for 8,138 square feet of office and laboratory space with a one year term. Between January 2015 and October 2018, the Company entered into a series of lease amendments to increase the amount of leased space to 27,280 square feet and extend the expiration of the lease to February 2023. The lease agreement includes annual rent escalations. Under the lease and subsequent amendments, the landlord provided approximately $ 1.9 million in free rent and lease incentives. The Company records rent expense on a straight-line basis over the effective term of the lease, including any free rent periods and incentives. As the interest rate implicit in lease arrangements is typically not readily available, in calculating the present value of the lease payments, the Company has utilized its incremental borrowing rate, which is determined based on the prevailing market rates for collateralized debt with maturity dates commensurate with the term of its lease . The Company’s facility lease is a net lease, as the non-lease components (i.e. common area maintenance) are paid separately from rent based on actual costs incurred. Therefore, the non-lease components were not included in the right-of-use asset and liability and are reflected as an expense in the period incurred. ​ As of September 30, 2020 and December 31, 2019, the right-of-use asset under operating lease was $ 1.8 million and $ 2.3 million, respectively. The elements of lease expense for the three and nine months ended September 30, 2020 and 2019 were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Nine Months Ended ​ Statements of operations and September 30, ​ September 30, ​ ​ comprehensive loss location ​ 2020 2019 ​ 2020 2019 ​ Costs of operating lease ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating lease costs ​ Research and development, General and administrative ​ $ 239 ​ $ 239 ​ $ 718 ​ $ 720 ​ Costs of non-lease components (previously common area maintenance) ​ Research and development, General and administrative ​ ​ 87 ​ ​ 81 ​ ​ 263 ​ ​ 243 ​ Total operating lease cost ​ ​ ​ $ 326 ​ $ 320 ​ $ 981 ​ $ 963 ​ Other Information ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating cash flows used for operating lease ​ ​ ​ $ 377 ​ $ 363 ​ $ 1,132 ​ $ 1,084 ​ Remaining lease term ​ ​ ​ 2.3 years ​ 3.3 years ​ 2.3 years ​ 3.3 years ​ Discount rate ​ ​ ​ 10.0 % ​ 10.0 % ​ 10.0 % ​ 10.0 % ​ ​ As of September 30, 2020, minimum rental commitments under this lease were as follows (in thousands): ​ ​ ​ ​ ​ Year Ended December 31 (in thousands) ​ ​ 2020* $ 290 2021 ​ ​ 1,260 2022 ​ 1,299 Total lease payments ​ 2,849 Less: imputed interest ​ ​ ( 312 ) Total $ 2,537 * Remainder of the year ​ 17 Table of Contents As of December 31, 2019, minimum rental commitments under this lease were as follows (in thousands): ​ ​ ​ ​ ​ Year Ended December 31 (in thousands) ​ ​ 2020 ​ $ 1,159 2021 ​ 1,260 2022 ​ ​ 1,299 Total lease payments ​ 3,718 Less: imputed interest ​ ​ ( 530 ) Total $ 3,188 ​ ​ ​ 12. Commitments and Contingencies ​ In August 2015, the Company entered into an agreement for a line of credit of $ 0.1 million for the purpose of issuing its landlord a letter of credit of $ 0.1 million as a security deposit under its facility lease. The Company pledged money market funds and marketable securities as collateral for the line of credit. For further discussion of the Company’s facility lease agreement, see Note 11. ​ Pursuant to the Company’s license agreements with each of Vernalis, Scripps and Monash, it has obligations to make future milestone and royalty payments to these parties, respectively. However, because these amounts are contingent, they have not been included on the Company’s balance sheet. For further discussion of the Vernalis, Scripps and Monash licensing agreements, see Note 5. ​ Indemnifications ​ In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third-party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has also entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by Delaware corporate law. There have been no claims to date and the Company has a directors and officers insurance policy that may enable it to recover a portion of any amounts paid for future claims. ​ Legal Proceedings ​ The Company is not a party to any material legal proceedings. ​ 18 Table of Contents 13. Subsequent Events ​ In October 2020, the Company announced the formation and launch of Angel Pharmaceuticals Co., Ltd. (“Angel Pharmaceuticals”), a new China based biopharmaceutical. The Company formed Angel Pharmaceuticals as a wholly-owned subsidiary and it launched with a post-money valuation of approximately $ 106.0 million, based on an approximate $ 41.0 million cash investment from a Chinese investor group that includes funds associated with Tigermed and Betta Pharmaceuticals, Hisun Pharmaceuticals and Zhejiang Puissance Capital, $ 6.6 million of such investments are subject to the satisfaction of certain customary conditions. Such cash is not available for Corvus’ use. Contemporaneously with the financing, Angel Pharmaceuticals obtained the rights to develop and commercialize the Company’s three clinical-stage candidates – ciforadenant, CPI-006 and CPI-818 – in greater China and obtained global rights to the Company’s BTK inhibitor preclinical programs. Under the collaboration, the Company will initially retain a 49.7 % equity stake in Angel Pharmaceuticals and will be entitled to designate three individuals on Angel’s five -person Board of Directors. The Company is currently in the process of finalizing the related accounting treatment of this transaction. ​ ​ 19 Table of Contents